This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



tasimelteon (Hetlioz®)


Reference No. 1077

Publication date:
10/12/2015


Appraisal information

tasimelteon (Hetlioz®) 20 mg hard capsules


Company: Vanda Pharmaceuticals Inc
BNF category: Central nervous system
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 09/12/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

This product is currently not marketed in the UK. In the absence of a submission from the holder of the marketing authorisation, tasimelteon (Hetlioz®) cannot be endorsed for use within NHS Wales for the treatment of non-24-hour sleep-wake disorder (non-24) in totally blind adults.